Rumbling beneath the Trump administration’s hostility toward mRNA vaccines has been a larger question of whether the FDA will ...

THE VACCINE MAKER MODERNA decided this past week to tell the world about bad news it had received from the federal government ...

Refusal to review the submission is inconsistent with feedback at pre-Phase 3 and pre-submission consultations; Moderna ...

Co-infection of influenza virus and SARS-CoV-2 can lead to more severe disease than infection of either alone.

Moderna shares sink 10% after FDA issues Refusal-to-File letter for its mRNA-1010 flu vaccine, citing trial design concerns despite no safety flags.

The Food and Drug Administration's about-face comes a little more than a week after the agency refused to consider the ...

BioNTech SE is transitioning from a COVID-19 vaccine story to a late-stage oncology platform with a robust $17B cash position. Click to read why BNTX is a Buy.

Drug observers puzzled by vaccine maker, which made a killing on COVID-19, failing to read the room with new administration. Moderna puts heat on FDA vaccines chief who's already been rebuked once by ...

The suicidal impulse so often begins with left-leaning researchers in elite universities (i.e., the tenured in search of a novel, grant-getting theory). They begin insisting that a new existential ...

Victor Davis Hanson traces how elite-driven “collective madness” on climate, COVID, gender, crime, and immigration becomes ...

Friday, February 13th, 2026As far as economic reports go, the good news just keeps on coming. Seemingly running on a separate track from investor fears about AI’s future role in the economy, today’s ...

Deutsche Bank upgraded Rivian to ‘Buy’ from ‘Hold’ and raised its price target to $23 from $16. ・UBS said it remains “excited ...